Received Dec 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | IM |
Muscle weakness; This non-serious case was reported by a consumer via call center representative and described the occurrence of muscle weakness in a 73-year-old patient who received Herpes zoster (Shingles vaccine) for prophylaxis. On 14-OCT-2025, the patient received the 1st dose of Shingles vaccine (intramuscular). On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced muscle weakness (Verbatim: Muscle weakness). The outcome of the muscle weakness was not resolved. It was unknown if the reporter considered the muscle weakness to be related to Shingles vaccine. It was unknown if the company considered the muscle weakness to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 05-DEC-2025 The batch number was not provided, and we are unable to contact the reporter.